Houston, Texas
CNS clinical trials in Houston, TX
127 CNS studies are recruiting participants at sites in Houston as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Houston at a glance
- 127 studies are recruiting at a site in Houston.
- By phase: Phase 1 (5), Phase 1/2 (5), Phase 2 (16), Phase 2/3 (1), Phase 3 (41), Phase 4 (3), No phase (40), Observational (16). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (70), university, hospital or other (54), government (3).
- By research area: Depression (43), Parkinson's Disease (22), Epilepsy (21), Schizophrenia (16), Multiple Sclerosis (10), Migraine (8), Bipolar Disorder (5), ADHD (2).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Houston
Basic details from each study's public record (the 30 most recently updated of 127). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study sites
- Baylor College of Medicine · DM Clinical
- Registry record
- NCT07226661 · updated
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Study site
- Brain Health Consultants and TMS Center
- Registry record
- NCT06793397 · updated
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
- No phase
- Ages 22 to 85
- All sexes
- Sponsor
- Motif Neurotech, Inc.
- Study sites
- Brain Health Consultants and TMS Center · UTHealth Houston
- Registry record
- NCT07594483 · updated
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Study site
- Baylor College of Medicine
- Registry record
- NCT07284667 · updated
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- LivaNova
- Study site
- The University Of Texas Medical School At Houston - UT Center Of Excellence On Mood Disorders
- Registry record
- NCT03887715 · updated
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- DM Clinical Research
- Registry record
- NCT05850689 · updated
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
- Phase 2
- Ages 25 and older
- All sexes
- Sponsor
- M.D. Anderson Cancer Center
- Study site
- MD Anderson Cancer Center
- Registry record
- NCT06200155 · updated
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- Phase 3
- Ages 10 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Kaleidoscope Clinical Research
- Registry record
- NCT06372964 · updated
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Baylor College of Medicine
- Registry record
- NCT06559306 · updated
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- M.D. Anderson Cancer Center
- Study site
- The University of Texas M. D. Anderson Cancer Center
- Registry record
- NCT06801041 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Houston, TX on ClinicalTrials.gov.
Schizophrenia studies recruiting in Houston
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Phase 3
- Ages 13 to 17
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Memorial Hermann
- Registry record
- NCT07288567 · updated
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Evolution Research Group
- Registry record
- NCT07424404 · updated
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study sites
- Kaleidoscope Clinical Research · Red Oak Psychiatry Associates
- Registry record
- NCT06229210 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Houston, TX on ClinicalTrials.gov.
Bipolar disorder studies recruiting in Houston
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Baylor College of Medicine
- Study site
- Baylor College of Medicine
- Registry record
- NCT06476678 · updated
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Elevate Clinical Research-Houston
- Registry record
- NCT07140913 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Houston, TX on ClinicalTrials.gov.
ADHD studies recruiting in Houston
The Myelin Disorders Biorepository Project
- Observational
- All ages
- All sexes
- Sponsor
- Children's Hospital of Philadelphia
- Study sites
- Baylor College of Medicine (Texas Children's Hospital) · UT Health Houston
- Registry record
- NCT03047369 · updated
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study site
- Kaleidoscope Clinical Research
- Registry record
- NCT07759154 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Houston, TX on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Houston
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Texas MD Anderson Cancer Center ( Site 6920)
- Registry record
- NCT06469944 · updated
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Boston Scientific Corporation
- Study site
- Houston Methodist Research Institute
- Registry record
- NCT02071134 · updated
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Oncology Consultants P.A. ( Site 0113)
- Registry record
- NCT06345729 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Kelsey-Seybold Clinic ( Site 0040) · Kelsey-Seybold Clinic - North Houston Campus ( Site 0096)
- Registry record
- NCT06841354 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Houston Methodist Hospital ( Site 6057)
- Registry record
- NCT06952504 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Kelsey-Seybold Clinic ( Site 0042) · Kelsey-Seybold Clinic ( Site 0088) · Oncology Consultants P.A. ( Site 0073)
- Registry record
- NCT06966700 · updated
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
- Observational
- Ages 50 to 85
- All sexes
- Sponsor
- CND Life Sciences
- Study site
- Baylor College of Medicine
- Registry record
- NCT07428447 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Houston Methodist Cancer Center ( Site 0191) · MD Anderson Cancer Center ( Site 0150) · Memorial Hermann Cancer Center ( Site 0172)
- Registry record
- NCT06623422 · updated
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Houston Methodist Hospital-Obstetrics and Gynecology ( Site 6010)
- Registry record
- NCT07216703 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Houston, TX on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UT MD Anderson Cancer Center
- Registry record
- NCT03816345 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Houston, TX on ClinicalTrials.gov.
Epilepsy studies recruiting in Houston
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Registry record
- NCT07594119 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Houston, TX on ClinicalTrials.gov.
Migraine studies recruiting in Houston
Study of EVO756 in Adults With Migraine
- Phase 2
- Ages 18 to 64
- All sexes
- Sponsor
- Evommune, Inc.
- Study sites
- Mercury Clinical Research Inc. - Houston Neurology Associates · SFF Medical Research Group LLC
- Registry record
- NCT07616128 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Houston, TX on ClinicalTrials.gov.
Ask about studies near Houston
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Texas
All Texas locations
263 studies recruiting across 56 cities.
Austin
69 studies recruiting.
Dallas
66 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections